326 related articles for article (PubMed ID: 22685582)
21. Examining the safety of PPAR agonists - current trends and future prospects.
Bortolini M; Wright MB; Bopst M; Balas B
Expert Opin Drug Saf; 2013 Jan; 12(1):65-79. PubMed ID: 23134541
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)α/γ agonist aleglitazar in attenuating TNF-α-mediated inflammation and insulin resistance in human adipocytes.
Massaro M; Scoditti E; Pellegrino M; Carluccio MA; Calabriso N; Wabitsch M; Storelli C; Wright M; De Caterina R
Pharmacol Res; 2016 May; 107():125-136. PubMed ID: 26976796
[TBL] [Abstract][Full Text] [Related]
23. Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor α/γ.
dos Santos JC; Bernardes A; Giampietro L; Ammazzalorso A; De Filippis B; Amoroso R; Polikarpov I
J Struct Biol; 2015 Sep; 191(3):332-40. PubMed ID: 26185032
[TBL] [Abstract][Full Text] [Related]
24. Virtual identification of novel PPARα/γ dual agonists by scaffold hopping of saroglitazar.
Jia WQ; Jing Z; Liu X; Feng XY; Liu YY; Wang SQ; Xu WR; Liu JW; Cheng XC
J Biomol Struct Dyn; 2018 Oct; 36(13):3496-3512. PubMed ID: 29081262
[TBL] [Abstract][Full Text] [Related]
25. Identification of dual PPARα/γ agonists and their effects on lipid metabolism.
Gao Q; Hanh J; Váradi L; Cairns R; Sjöström H; Liao VW; Wood P; Balaban S; Ong JA; Lin HY; Lai F; Hoy AJ; Grewal T; Groundwater PW; Hibbs DE
Bioorg Med Chem; 2015 Dec; 23(24):7676-84. PubMed ID: 26616289
[TBL] [Abstract][Full Text] [Related]
26. Discovery of New Dual-Target Agents Against PPAR-γ and α-Glucosidase Enzymes with Molecular Modeling Methods: Molecular Docking, Molecular Dynamic Simulations, and MM/PBSA Analysis.
Kaya S; Tatar-Yılmaz G; Aktar BSK; Emre EEO
Protein J; 2024 Jun; 43(3):577-591. PubMed ID: 38642318
[TBL] [Abstract][Full Text] [Related]
27. Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes.
Nicholls SJ; Uno K
Diab Vasc Dis Res; 2012 Apr; 9(2):89-94. PubMed ID: 22407927
[TBL] [Abstract][Full Text] [Related]
28. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
Fiévet C; Fruchart JC; Staels B
Curr Opin Pharmacol; 2006 Dec; 6(6):606-14. PubMed ID: 16973418
[TBL] [Abstract][Full Text] [Related]
29. Synthesis of novel PPARα/γ dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design program PROTOBUILD.
Bhurruth-Alcor Y; Røst T; Jorgensen MR; Kontogiorgis C; Skorve J; Cooper RG; Sheridan JM; Hamilton WD; Heal JR; Berge RK; Miller AD
Org Biomol Chem; 2011 Feb; 9(4):1169-88. PubMed ID: 21157612
[TBL] [Abstract][Full Text] [Related]
30. The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Current Perspective.
Ahsan W
Curr Pharm Des; 2019; 25(23):2540-2554. PubMed ID: 31333088
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and Structure-Activity Relationships of 2-Aminoacetamide Derivatives as Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists.
Shibata Y; Kagechika K; Ota M; Yamaguchi M; Setoguchi M; Kubo H; Chiba K; Takano H; Akiyama C; Ono M; Nishi M; Usui H
Chem Pharm Bull (Tokyo); 2015; 63(8):591-602. PubMed ID: 26235167
[TBL] [Abstract][Full Text] [Related]
32. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
[TBL] [Abstract][Full Text] [Related]
33. Dual Peroxisome Proliferator-Activated Receptor-alpha/gamma Agonists : In the Treatment of Type 2 Diabetes Mellitus and the Metabolic Syndrome.
Pershadsingh HA
Treat Endocrinol; 2006; 5(2):89-99. PubMed ID: 16542049
[TBL] [Abstract][Full Text] [Related]
34. Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors α/γ dual agonists.
Fracchiolla G; Laghezza A; Piemontese L; Parente M; Lavecchia A; Pochetti G; Montanari R; Di Giovanni C; Carbonara G; Tortorella P; Novellino E; Loiodice F
Bioorg Med Chem; 2012 Mar; 20(6):2141-51. PubMed ID: 22341573
[TBL] [Abstract][Full Text] [Related]
35. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.
Ahmed I; Furlong K; Flood J; Treat VP; Goldstein BJ
Am J Ther; 2007; 14(1):49-62. PubMed ID: 17303976
[TBL] [Abstract][Full Text] [Related]
36. Sex-specific differences in Type 2 Diabetes Mellitus and dyslipidemia therapy: PPAR agonists.
Benz V; Kintscher U; Foryst-Ludwig A
Handb Exp Pharmacol; 2012; (214):387-410. PubMed ID: 23027460
[TBL] [Abstract][Full Text] [Related]
37. Structure-based virtual screening and discovery of New PPARδ/γ dual agonist and PPARδ and γ agonists.
Maltarollo VG; Togashi M; Nascimento AS; Honorio KM
PLoS One; 2015; 10(3):e0118790. PubMed ID: 25767888
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and structure-activity relationships of novel zwitterionic compounds as peroxisome proliferator activated receptor α/γ dual agonists with improved physicochemical properties.
Shibata Y; Kagechika K; Yamaguchi M; Yoshikawa K; Chiba K; Takano H; Akiyama C; Ono M; Nishi M; Kubo H; Kobayashi Y; Usui H
Chem Pharm Bull (Tokyo); 2013; 61(12):1248-63. PubMed ID: 24292787
[TBL] [Abstract][Full Text] [Related]
39. Molecular determinants for nuclear receptors selectivity: chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors α/γ agonists.
Carrieri A; Giudici M; Parente M; De Rosas M; Piemontese L; Fracchiolla G; Laghezza A; Tortorella P; Carbonara G; Lavecchia A; Gilardi F; Crestani M; Loiodice F
Eur J Med Chem; 2013 May; 63():321-32. PubMed ID: 23502212
[TBL] [Abstract][Full Text] [Related]
40. Quantitative structure-activity relationship models with receptor-dependent descriptors for predicting peroxisome proliferator-activated receptor activities of thiazolidinedione and oxazolidinedione derivatives.
Lather V; Kairys V; Fernandes MX
Chem Biol Drug Des; 2009 Apr; 73(4):428-41. PubMed ID: 19243388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
